Literature DB >> 1643754

IL-4 and IL-2 promote human T-cell proliferation through symmetrical but independent pathways.

R Or1, H Renz, N Terada, E W Gelfand.   

Abstract

The role of IL-4 and IL-2 on normal human T-cell activation and proliferation was studied. Both IL-2 and IL-4 were unable to induce proliferation of resting T cells. Therefore, we investigated their effect and the regulation of the T-cell proliferative response in competent T cells. T cells were rendered competent following incubation with PDB/ionomycin for 30 min or suboptimal concentrations of PHA for 60 min. Cells were then washed and recultured with PDB, IL-2, or IL-4 in the second or progression phase of the culture. Cells cultured in medium alone in this phase did not proliferate. IL-2 and IL-4 independently promoted competent T cells to proliferate to a similar degree as the response to PDB and the combination of IL-2 and IL-4 was not additive. The induction of competence and subsequent responsiveness to IL-2 and IL-4 could be maintained for about 24 hr after which time they become gradually less responsive to the interleukin in the progression phase. Addition of anti-IL-2R mAb or anti-IL-2 mAb resulted in selective inhibition of IL-2-mediated proliferation only. Similarly, addition of anti-IL-4 mAb resulted only in inhibition of IL-4-mediated proliferation. Addition of IL-2 during the progression phase led to an enhancement of IL-2R (TAC) expression while IL-4 did not affect IL-2R expression. The production of IL-2 and IL-4 by competent T cells could not be enhanced by the noncorresponding lymphokine. These results on the protein level were confirmed at the mRNA level as well and demonstrated that only PDB and IL-2 could induce IL-2 mRNA and PDB and IL-4 enhanced IL-4 mRNA. The immunosuppressive drug, cyclosporin A, failed to inhibit progression triggered by PDB, IL-2 or IL-4 in competent T cells. These findings suggest that IL-2 and IL-4 trigger T-cell proliferation through symmetrical, but independent pathways.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1643754     DOI: 10.1016/0090-1229(92)90202-y

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  7 in total

1.  Characterization and functional studies of forkhead box protein 3(-) lymphocyte activation gene 3(+) CD4(+) regulatory T cells induced by mucosal B cells.

Authors:  K-H Chu; B-L Chiang
Journal:  Clin Exp Immunol       Date:  2015-05       Impact factor: 4.330

2.  IL4 receptor α mediates enhanced glucose and glutamine metabolism to support breast cancer growth.

Authors:  Katherine T Venmar; Danielle W Kimmel; David E Cliffel; Barbara Fingleton
Journal:  Biochim Biophys Acta       Date:  2015-03-04

Review 3.  Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer.

Authors:  Ruth Whittington; Diana Faulds
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

4.  Impairment of T-cell growth-promoting lymphokines in human insulin-dependent diabetes mellitus.

Authors:  G Valerio; N Gasparini; R Badolato; S Di Maio; A Tenore
Journal:  Acta Diabetol       Date:  1994-04       Impact factor: 4.280

5.  Cancer Conditioned Medium Modulates Functional and Phenotypic Properties of Human Decidua Parietalis Mesenchymal Stem/Stromal Cells.

Authors:  E Bahattab; T Khatlani; F M Abomaray; S A Messaoudi; M H Abumaree
Journal:  Tissue Eng Regen Med       Date:  2019-11-01       Impact factor: 4.169

6.  Intracellular delivery of HA1 subunit antigen through attenuated Salmonella Gallinarum act as a bivalent vaccine against fowl typhoid and low pathogenic H5N3 virus.

Authors:  Nitin Machindra Kamble; Kim Je Hyoung; John Hwa Lee
Journal:  Vet Res       Date:  2017-08-07       Impact factor: 3.683

7.  Cytokines Stimulate the Release of Microvesicles from Myeloid Cells Independently from the P2X7 Receptor/Acid Sphingomyelinase Pathway.

Authors:  Federico Colombo; Mattia Bastoni; Annamaria Nigro; Paola Podini; Annamaria Finardi; Giacomo Casella; Menon Ramesh; Cinthia Farina; Claudia Verderio; Roberto Furlan
Journal:  Front Immunol       Date:  2018-02-07       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.